Tracking New GLP-1 Manufacturing Plant Announcements
Novo Nordisk, Eli Lilly, and their contract manufacturers have announced new production facilities across multiple countries as demand has outpaced supply.
By the GLP Semaglutide editorial team · Last updated August 2, 2025
Both major GLP-1 manufacturers, along with contract manufacturing partners, have announced new or expanded production facilities in multiple countries, reflecting the scale of investment required to meet global demand for injectable GLP-1 drugs.
Why capacity is the real bottleneck
Manufacturing complex injectable peptide drugs at scale requires specialized equipment, validated sterile production lines, and regulatory inspection before new capacity can legally contribute to supply — a multi-year process even with committed capital.
Tracking real supply impact
A new facility announcement is not the same as new supply hitting the market. The FDA's shortage database remains the most direct indicator of whether announced capacity has translated into resolved shortages for specific products.
Primary sources